» Articles » PMID: 36302338

The Effect of Menopause on Lipoprotein (a) Concentrations: A Systematic Review and Meta-analysis

Overview
Journal Maturitas
Specialty Geriatrics
Date 2022 Oct 27
PMID 36302338
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Transition to menopause has been associated with an increased risk of cardiovascular disease (CVD), attributed mainly to atherogenic dyslipidemia. Whether lipoprotein (a) [Lp(a)], an independent cardiovascular risk factor, also contributes to menopause-associated CVD has not yet been clarified. The aim of this study was to systematically investigate and meta-analyze the best available evidence regarding the effect of menopause on Lp(a) concentrations.

Methods: A comprehensive search was conducted in PubMed and Scopus databases up to March 8th, 2022. Data were expressed as weighted mean difference (WMD) with 95 % confidence intervals (CI). The I index was employed to assess heterogeneity.

Results: Seventeen studies were included in the qualitative and 15 in the quantitative analysis, yielding 4686 premenopausal and 8274 postmenopausal women. Lp(a) concentrations were lower in premenopausal than in postmenopausal women [WMD -3.77 (95 % CI -5.37, -2.18) mg/dl, p < 0.001; I 99%, p < 0.001]. This difference was maintained when the analysis was restrained to good-quality studies (n = 9). Four studies included pre- and postmenopausal women, matched for age, and these found no difference in Lp(a) concentrations between groups [WMD -1.22 (95 % CI -3.15, 0.72) mg/dl, p < 0.001; I 99%, p < 0.001]. Three studies provided data for Lp(a) in women before and after bilateral oophorectomy, and these found no difference between them [WMD -3.38 (95 % CI -7.29, 0.54) mg/dl, p = 0.09; I 0%, p < 0.44].

Conclusions: Transition to menopause may increase Lp(a) concentrations, although the effect of aging cannot be excluded by current data.

Citing Articles

Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers.

Steinhagen-Thiessen E, Daccord M, Print E, Wang Y, Shipton J, Rijken I Patient Prefer Adherence. 2025; 19:395-405.

PMID: 40008374 PMC: 11853138. DOI: 10.2147/PPA.S478623.


Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study.

Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J Ann Med. 2025; 57(1):2454975.

PMID: 39898960 PMC: 11792142. DOI: 10.1080/07853890.2025.2454975.


Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.

Luca F, Pavan D, Gulizia M, Manes M, Abrignani M, Benedetto F Eur Heart J Suppl. 2024; 26(Suppl 2):ii264-ii293.

PMID: 38784671 PMC: 11110461. DOI: 10.1093/eurheartjsupp/suae034.


Lipoprotein(a): Emerging insights and therapeutics.

Kaur G, Abdelrahman K, Berman A, Biery D, Shiyovich A, Huck D Am J Prev Cardiol. 2024; 18:100641.

PMID: 38646022 PMC: 11033089. DOI: 10.1016/j.ajpc.2024.100641.


Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?.

Tsioulos G, Kounatidis D, Vallianou N, Poulaki A, Kotsi E, Christodoulatos G Int J Mol Sci. 2024; 25(6).

PMID: 38542510 PMC: 10971284. DOI: 10.3390/ijms25063537.